1 Start 2 Page break 3 Page break 4 Page break 5 Complete Page 1 of 5 Please answer the following questions related to the upcoming Women's Masterclass meeting. The purpose is to test your knowledge prior to the education and is important for our evaluation of future programs. Thank you in advance. Email address * First Name * Last Name * Degree * A lower ABI (ankle brachial index) indicates a _________ risk for PAD * Lower Higher Intermediate ABI is not associated with risk of PAD Which of the following adverse events is often underrecognized but has major impacts in PAD patients? * Myocardial infarction Stroke Acute limb ischemia Claudication Coronary artery stenosis Which of the following is TRUE about the COMPASS trial with low-dose rivaroxaban + aspirin in patients with PAD? * There was no net benefit in patients with diabetes vs. patients without diabetes Net clinical benefit was similar in patients with and without diabetes Bleeding risk was significantly higher in patients with diabetes Unsure Which of the following is TRUE about the efficacy and safety of rivaroxaban + aspirin compared to aspirin in the VOYAGER-PAD trial of PAD patients who had undergone lower-extremity revascularization? * Decreased risk of adverse CV and limb events, but increased ISTH AND TIMI major bleeding Decreased risk of adverse CV and limb events and increased ISTH major bleeding Decreased risk of adverse CV events with no increased bleeding risk Decreased risk of adverse limb events and increased ISTH and TIMI major bleeding A 68-year-old woman with newly-diagnosed PAD, long-standing diabetes and hypertension is having trouble walking and exercising due to lower extremity claudication. According to guidelines and current evidence, which of the following regimens would be the most appropriate to decrease the risk of major adverse cardiovascular events (MACE) or major adverse limb events (MALE)? * Aspirin Clopidogrel Dual antiplatelet therapy (aspirin + clopidogrel) Low-dose rivaroxaban + aspirin Patient is not a candidate for additional drug therapy A 78-year-old female with 6-year history of T2DM, history of PAD, no history of MI, stroke, or HF, and no known microvascular complications. 3-years ago had the onset of angina, and coronary angiogram revealed 85% lesion in her LAD and 50% lesion in her circumflex both treated with drug eluting stents, has been angina-free since. She is on ASA and ticagrelor for antiplatelet therapy, but calls you 3 months later as she had some melena, and a subsequent scope revealed a small gastric ulcer for which she was started on omeprazole. What would you do next? * Stop the ASA and ticagrelor Continue the ASA but stop the ticagrelor Stop the ASA and continue the ticagrelor Leave this field blank
